NDAINTRAVENOUSPOWDER
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
LOCAMETZ (kit for the preparation of gallium ga 68 gozetotide) by Novartis is 68 gozetotide binds to psma. First approved in 2022.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOCAMETZ is a gallium-68 gozetotide kit for preparation of a PET radiopharmaceutical that targets PSMA-expressing cells, particularly in prostate cancer. The gozetotide ligand binds to prostate-specific membrane antigen (PSMA) overexpressed on malignant prostate cancer cells, while gallium-68 enables PET imaging. This diagnostic agent is administered intravenously as a reconstituted powder.
Peak9.7 years to LOE
Product is at peak commercial phase with no current competitive pressure, suggesting stable team size and focused commercial execution around diagnostic imaging partnerships and nuclear medicine channels.
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows PET.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LOCAMETZ is a specialized diagnostic oncology asset at peak commercial maturity under Novartis, requiring deep expertise in nuclear medicine, prostate cancer pathways, and hospital/diagnostic center channels. Career growth is strong within diagnostic imaging commercialization, reimbursement strategy, and clinical decision-support roles given the product's market position and long patent protection.
Diagnostic Product Manager
Worked on LOCAMETZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.